📰 Two Part News
Two Part News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Two Part. Real-time updates on events, politics, business and more.
May 2, 2024
Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR, MI / ACCESSWIRE / May 2, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-ca...
January 9, 2024
TOPEKA (KSNT) – On the latest episode of Inside Kansas Politics, it's part one of our two-part special discussing the top political topics of 2024.
May 22, 2023
Part One of Two Part Series Gaining Student Growth with ESSER By Ann M Ennis MAY 22, 2023 During the April 10 EVSC School Board meeting trustees voted to sign a contract with Ten Adams, a local, marketing and advertising firm. Per the agenda, the EVSC will spend $250,000 from ESSER funding (E
May 21, 2023
: Gun control, then and now: GOP and NRA actions over AR-15s continue to stall progress - This is part two of a two-part series on this history of gun control policy. You can read part one here. Part one of this series looked at how the Thompson submachine gun, popularly known as the Tommy gun, was originally developed as a weapon of war and then marketed to law enforcement agencies and the military.
April 19, 2023
Master Bond's fast curing adhesives cure within a few seconds to several minutes.
September 27, 2022
A free training series is teaching community leaders to identify and prevent human trafficking in Louisville.
December 10, 2021
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
December 10, 2021
/PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...
December 10, 2021
New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates
December 10, 2021
/PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...